Success Stories

RDD Pharma

RDD aims to provide targeted pharmacological treatments for diseases of the anorectal region such as anal fissures, fecal incontinence and pruritus ani. Additionally, a molecule targeting radiation proctitis is in preclinical development.

RDD Pharma, a leader in developing treatments for anorectal disorders, has announced that the European Medicines Agency’s Committee for Orphan Medicinal Products has granted orphan designation for RDD-0315,  an investigational drug for the treatment of fecal incontinence in patients with spinal cord injury. The committee recognised that RDD-0315 may be of significant benefit to spinal cord injury patients affected by fecal incontinence.

RDD Pharma
Share this Page:
Facebook Twitter Google LinkedIn Email